drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00295 | DB00960 | 475 | 887 | [
"DDInter1244",
"DDInter1471"
] | Morphine | Pindolol | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Moderate | 1 | [
[
[
475,
24,
887
]
],
[
[
475,
24,
819
],
[
819,
40,
887
]
],
[
[
475,
63,
88
],
[
88,
40,
887
]
],
[
[
475,
24,
1121
],
[
1121,
1,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
[
"A... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol (Compound) resembles Pindolol (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Pindolol (Compound)
Morphine... |
DB00860 | DB11730 | 891 | 351 | [
"DDInter1513",
"DDInter1588"
] | Prednisolone | Ribociclib | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
891,
24,
351
]
],
[
[
891,
24,
283
],
[
283,
62,
351
]
],
[
[
891,
63,
288
],
[
288,
24,
351
]
],
[
[
891,
24,
987
],
[
987,
63,... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Butalbital and Buta... |
DB00491 | DB01155 | 127 | 872 | [
"DDInter1217",
"DDInter813"
] | Miglitol | Gemifloxacin | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Moderate | 1 | [
[
[
127,
24,
872
]
],
[
[
127,
24,
739
],
[
739,
1,
872
]
],
[
[
127,
63,
1467
],
[
1467,
1,
872
]
],
[
[
127,
24,
945
],
[
945,
40,... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gemifloxacin (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Enoxacin and Enoxacin (Compound) resembles Gemifloxacin (Compound)
... |
DB00813 | DB09073 | 704 | 951 | [
"DDInter722",
"DDInter1379"
] | Fentanyl | Palbociclib | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
704,
24,
951
]
],
[
[
704,
24,
1476
],
[
1476,
63,
951
]
],
[
[
704,
40,
1454
],
[
1454,
24,
951
]
],
[
[
704,
24,
259
],
[
259,
... | [
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Fentanyl (Compound) resembles Sufentanil (Compound) and Sufentanil may cause a moderate interaction that could ex... |
DB01105 | DB01132 | 222 | 1,130 | [
"DDInter1665",
"DDInter1472"
] | Sibutramine | Pioglitazone | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
222,
24,
1130
]
],
[
[
222,
6,
8374
],
[
8374,
45,
1130
]
],
[
[
222,
21,
28661
],
[
28661,
60,
1130
]
],
[
[
222,
25,
851
],
[
851,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Sibutramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Sibutramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pioglitazone (Compound)
Sibutramine (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Pioglitazone (Compound)
Sibutramine may lead to a major life threatening interaction when taken with... |
DB00539 | DB01599 | 11 | 1,232 | [
"DDInter1837",
"DDInter1523"
] | Toremifene | Probucol | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | Major | 2 | [
[
[
11,
25,
1232
]
],
[
[
11,
23,
112
],
[
112,
23,
1232
]
],
[
[
11,
64,
1555
],
[
1555,
24,
1232
]
],
[
[
11,
25,
927
],
[
927,
63... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Probucol"
]
],
[
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazo... | Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Probucol
Toremifene may lead to a major life threatening interaction when taken with Oxaliplatin and Oxaliplatin may caus... |
DB00748 | DB00981 | 662 | 1,528 | [
"DDInter297",
"DDInter1463"
] | Carbinoxamine | Physostigmine (ophthalmic) | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Physostigmine is a carbamate ester and an indole alkaloid. It has a role as a miotic, an EC 3.1.1.8 (cholinesterase) inhibitor and an antidote to curare poisoning. | Moderate | 1 | [
[
[
662,
24,
1528
]
],
[
[
662,
21,
28751
],
[
28751,
60,
1528
]
],
[
[
662,
63,
508
],
[
508,
24,
1528
]
],
[
[
662,
24,
1511
],
[
1511,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effe... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Carbinoxamine (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Physostigmine (Compound)
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken... |
DB00927 | DB00980 | 1,559 | 969 | [
"DDInter712",
"DDInter1564"
] | Famotidine | Ramelteon | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Moderate | 1 | [
[
[
1559,
24,
969
]
],
[
[
1559,
6,
10215
],
[
10215,
45,
969
]
],
[
[
1559,
21,
28714
],
[
28714,
60,
969
]
],
[
[
1559,
24,
1619
],
[
16... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Famotidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)"... | Famotidine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Ramelteon (Compound)
Famotidine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Ramelteon (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucapar... |
DB00108 | DB01042 | 1,066 | 1,307 | [
"DDInter1268",
"DDInter1144"
] | Natalizumab | Melphalan | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Major | 2 | [
[
[
1066,
25,
1307
]
],
[
[
1066,
25,
168
],
[
168,
23,
1307
]
],
[
[
1066,
23,
1193
],
[
1193,
62,
1307
]
],
[
[
1066,
64,
66
],
[
66,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Melphalan"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} ... | Natalizumab may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Melphalan
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may c... |
DB00563 | DB00994 | 663 | 361 | [
"DDInter1174",
"DDInter1277"
] | Methotrexate | Neomycin | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | Moderate | 1 | [
[
[
663,
24,
361
]
],
[
[
663,
63,
1647
],
[
1647,
24,
361
]
],
[
[
663,
21,
28722
],
[
28722,
60,
361
]
],
[
[
663,
63,
1252
],
[
1252,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Neomycin
Methotrexate (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Neomycin (Compound)
Methot... |
DB00365 | DB01377 | 839 | 1,283 | [
"DDInter842",
"DDInter1119"
] | Grepafloxacin | Magnesium oxide | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Moderate | 1 | [
[
[
839,
24,
1283
]
],
[
[
839,
25,
167
],
[
167,
23,
1283
]
],
[
[
839,
24,
263
],
[
263,
62,
1283
]
],
[
[
839,
23,
60
],
[
60,
23... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydrocortisone"
],
[
... | Grepafloxacin may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Axitinib and Axitin... |
DB00242 | DB09330 | 1,064 | 985 | [
"DDInter392",
"DDInter1352"
] | Cladribine | Osimertinib | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
1064,
25,
985
]
],
[
[
1064,
64,
168
],
[
168,
23,
985
]
],
[
[
1064,
25,
134
],
[
134,
24,
985
]
],
[
[
1064,
64,
66
],
[
66,
2... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} ... | Cladribine may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Cladribine may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may cause a moderate int... |
DB00467 | DB11110 | 1,467 | 603 | [
"DDInter644",
"DDInter1115"
] | Enoxacin | Magnesium citrate | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
1467,
24,
603
]
],
[
[
1467,
40,
246
],
[
246,
24,
603
]
],
[
[
1467,
25,
870
],
[
870,
24,
603
]
],
[
[
1467,
64,
251
],
[
251,
... | [
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may cause a ... | Enoxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Enoxacin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that cou... |
DB00065 | DB11760 | 581 | 119 | [
"DDInter923",
"DDInter1742"
] | Infliximab | Talazoparib | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Major | 2 | [
[
[
581,
25,
119
]
],
[
[
581,
24,
66
],
[
66,
24,
119
]
],
[
[
581,
24,
1129
],
[
1129,
63,
119
]
],
[
[
581,
25,
713
],
[
713,
24,... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizuma... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e s... |
DB01173 | DB01181 | 358 | 1,532 | [
"DDInter1349",
"DDInter906"
] | Orphenadrine | Ifosfamide | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
358,
24,
1532
]
],
[
[
358,
6,
8374
],
[
8374,
45,
1532
]
],
[
[
358,
21,
28956
],
[
28956,
60,
1532
]
],
[
[
358,
40,
307
],
[
307,
... | [
[
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Orphenadrine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Orphenadrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ifosfamide (Compound)
Orphenadrine (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Ifosfamide (Compound)
Orphenadrine (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction t... |
DB00405 | DB00514 | 128 | 506 | [
"DDInter517",
"DDInter527"
] | Dexbrompheniramine | Dextromethorphan | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Moderate | 1 | [
[
[
128,
24,
506
]
],
[
[
128,
63,
534
],
[
534,
40,
506
]
],
[
[
128,
63,
421
],
[
421,
24,
506
]
],
[
[
128,
24,
108
],
[
108,
62,... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trama... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tramadol and Tramadol (Compound) resembles Dextromethorphan (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone may cause a moderat... |
DB00009 | DB00975 | 1,271 | 1,317 | [
"DDInter56",
"DDInter573"
] | Alteplase | Dipyridamole | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Moderate | 1 | [
[
[
1271,
24,
1317
]
],
[
[
1271,
23,
1631
],
[
1631,
62,
1317
]
],
[
[
1271,
24,
958
],
[
958,
63,
1317
]
],
[
[
1271,
24,
1230
],
[
1230... | [
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
]
],
[
[
"Alteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
... | Alteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Dipyridamole
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba and Ginkgo bilo... |
DB00813 | DB09036 | 704 | 812 | [
"DDInter722",
"DDInter1668"
] | Fentanyl | Siltuximab | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Moderate | 1 | [
[
[
704,
24,
812
]
],
[
[
704,
1,
371
],
[
371,
24,
812
]
],
[
[
704,
40,
1454
],
[
1454,
24,
812
]
],
[
[
704,
24,
259
],
[
259,
24... | [
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Fentanyl",
"{u} (Compound) resembles {v} (Compound)",
"Propafenone"
],
[
"Propafenone",
"{u} may cause a moderate ... | Fentanyl (Compound) resembles Propafenone (Compound) and Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Fentanyl (Compound) resembles Sufentanil (Compound) and Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Fe... |
DB00994 | DB01339 | 361 | 728 | [
"DDInter1277",
"DDInter1922"
] | Neomycin | Vecuronium | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide ad... | Major | 2 | [
[
[
361,
25,
728
]
],
[
[
361,
64,
1610
],
[
1610,
1,
728
]
],
[
[
361,
25,
1579
],
[
1579,
40,
728
]
],
[
[
361,
21,
28746
],
[
28746,
... | [
[
[
"Neomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vecuronium"
]
],
[
[
"Neomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rocuronium"
],
[
"Rocuronium",
"{u} (Comp... | Neomycin may lead to a major life threatening interaction when taken with Rocuronium and Rocuronium (Compound) resembles Vecuronium (Compound)
Neomycin may lead to a major life threatening interaction when taken with Pancuronium and Pancuronium (Compound) resembles Vecuronium (Compound)
Neomycin (Compound) causes Eryth... |
DB00489 | DB06292 | 17 | 549 | [
"DDInter1704",
"DDInter474"
] | Sotalol | Dapagliflozin | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
17,
24,
549
]
],
[
[
17,
24,
1344
],
[
1344,
40,
549
]
],
[
[
17,
21,
28882
],
[
28882,
60,
549
]
],
[
[
17,
64,
79
],
[
79,
23,... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
... | Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Sotalol (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dapagliflozin (Compound)
Sota... |
DB00286 | DB01211 | 380 | 609 | [
"DDInter439",
"DDInter393"
] | Conjugated estrogens | Clarithromycin | The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
380,
24,
609
]
],
[
[
380,
6,
4973
],
[
4973,
45,
609
]
],
[
[
380,
21,
28789
],
[
28789,
60,
609
]
],
[
[
380,
63,
600
],
[
600,
... | [
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Conjugated estrogens",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bou... | Conjugated estrogens (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Conjugated estrogens (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Clarithromycin (Compound)
Conjugated estrogens may cause a moderate interaction that c... |
DB00030 | DB00945 | 1,685 | 1,479 | [
"DDInter934",
"DDInter20"
] | Insulin human | Acetylsalicylic acid | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Moderate | 1 | [
[
[
1685,
24,
1479
]
],
[
[
1685,
24,
461
],
[
461,
23,
1479
]
],
[
[
1685,
24,
651
],
[
651,
62,
1479
]
],
[
[
1685,
25,
246
],
[
246,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin ... |
DB00703 | DB00945 | 997 | 1,479 | [
"DDInter1167",
"DDInter20"
] | Methazolamide | Acetylsalicylic acid | A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Major | 2 | [
[
[
997,
25,
1479
]
],
[
[
997,
6,
10215
],
[
10215,
45,
1479
]
],
[
[
997,
21,
29250
],
[
29250,
60,
1479
]
],
[
[
997,
24,
714
],
[
714,... | [
[
[
"Methazolamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Methazolamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound... | Methazolamide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Acetylsalicylic acid (Compound)
Methazolamide (Compound) causes Polyuria (Side Effect) and Polyuria (Side Effect) is caused by Acetylsalicylic acid (Compound)
Methazolamide may cause a moderate interaction that could exacerbate diseases when t... |
DB11921 | DB12130 | 1,019 | 1,017 | [
"DDInter492",
"DDInter1094"
] | Deflazacort | Lorlatinib | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Major | 2 | [
[
[
1019,
25,
1017
]
],
[
[
1019,
63,
590
],
[
590,
24,
1017
]
],
[
[
1019,
64,
976
],
[
976,
24,
1017
]
],
[
[
1019,
24,
214
],
[
214,
... | [
[
[
"Deflazacort",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Aceto... | Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Deflazacort may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib ... |
DB00059 | DB01263 | 1,560 | 859 | [
"DDInter1404",
"DDInter1494"
] | Pegaspargase | Posaconazole | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
1560,
24,
859
]
],
[
[
1560,
25,
1101
],
[
1101,
23,
859
]
],
[
[
1560,
24,
482
],
[
482,
24,
859
]
],
[
[
1560,
24,
850
],
[
850,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexa... | Pegaspargase may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Posaconazole
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may ca... |
DB06016 | DB09564 | 1,508 | 1,296 | [
"DDInter300",
"DDInter930"
] | Cariprazine | Insulin degludec | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1508,
24,
1296
]
],
[
[
1508,
63,
274
],
[
274,
23,
1296
]
],
[
[
1508,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
1508,
24,
761
],
[
761,
... | [
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]... | Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide... |
DB00704 | DB00740 | 267 | 424 | [
"DDInter1263",
"DDInter1596"
] | Naltrexone | Riluzole | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi. | Moderate | 1 | [
[
[
267,
24,
424
]
],
[
[
267,
18,
2801
],
[
2801,
57,
424
]
],
[
[
267,
21,
29221
],
[
29221,
60,
424
]
],
[
[
267,
63,
305
],
[
305,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riluzole"
]
],
[
[
"Naltrexone",
"{u} (Compound) downregulates {v} (Gene)",
"PUF60"
],
[
"PUF60",
"{u} (Gene) is downregulated by {v} ... | Naltrexone (Compound) downregulates PUF60 (Gene) and PUF60 (Gene) is downregulated by Riluzole (Compound)
Naltrexone (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Riluzole (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Aspar... |
DB01406 | DB14723 | 984 | 159 | [
"DDInter472",
"DDInter1026"
] | Danazol | Larotrectinib | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
984,
24,
159
]
],
[
[
984,
62,
222
],
[
222,
23,
159
]
],
[
[
984,
25,
1135
],
[
1135,
23,
159
]
],
[
[
984,
24,
951
],
[
951,
2... | [
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Danazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
... | Danazol may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Danazol may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor... |
DB01285 | DB06710 | 708 | 1,546 | [
"DDInter445",
"DDInter1193"
] | Corticotropin | Methyltestosterone | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | A synthetic anabolic steroid used for treating men with testosterone deficiency or similar androgen replacement therapies. Also, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer. Methyltestosterone is a schedule III drug in the US. | Moderate | 1 | [
[
[
708,
24,
1546
]
],
[
[
708,
63,
312
],
[
312,
1,
1546
]
],
[
[
708,
63,
1026
],
[
1026,
40,
1546
]
],
[
[
708,
24,
1687
],
[
1687,
... | [
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eplerenone"
... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Eplerenone and Eplerenone (Compound) resembles Methyltestosterone (Compound)
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone and Oxandrolone (Compound) resembles Methyl... |
DB00533 | DB11312 | 1,416 | 298 | [
"DDInter1613",
"DDInter1542"
] | Rofecoxib | Protein C | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Protein C is an endogenously occurring plasma protein that plays a key role within the coagulation cascade. Protein C is a zymogen, or enzyme precursor, of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthesized in the liver. It is converted by the thrombin/thrombomodulin-complex on the e... | Moderate | 1 | [
[
[
1416,
24,
298
]
],
[
[
1416,
24,
500
],
[
500,
24,
298
]
],
[
[
1416,
63,
582
],
[
582,
24,
298
]
],
[
[
1416,
24,
1421
],
[
1421,
... | [
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxaparin"
],
[
... | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Protein C
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Reteplase and Reteplase ... |
DB00621 | DB01097 | 1,026 | 1,377 | [
"DDInter1357",
"DDInter1033"
] | Oxandrolone | Leflunomide | A synthetic hormone with anabolic and androgenic properties. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
1026,
25,
1377
]
],
[
[
1026,
7,
9489
],
[
9489,
46,
1377
]
],
[
[
1026,
18,
2049
],
[
2049,
57,
1377
]
],
[
[
1026,
21,
28931
],
[
28... | [
[
[
"Oxandrolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Oxandrolone",
"{u} (Compound) upregulates {v} (Gene)",
"WIF1"
],
[
"WIF1",
"{u} (Gene) is upregulated by {v} (Compound)",
... | Oxandrolone (Compound) upregulates WIF1 (Gene) and WIF1 (Gene) is upregulated by Leflunomide (Compound)
Oxandrolone (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is downregulated by Leflunomide (Compound)
Oxandrolone (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Leflu... |
DB00812 | DB01050 | 998 | 848 | [
"DDInter1451",
"DDInter900"
] | Phenylbutazone | Ibuprofen | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
998,
24,
848
]
],
[
[
998,
6,
16560
],
[
16560,
45,
848
]
],
[
[
998,
23,
16
],
[
16,
62,
848
]
],
[
[
998,
40,
362
],
[
362,
23... | [
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Phenylbutazone",
"{u} (Compound) binds {v} (Gene)",
"SLC22A8"
],
[
"SLC22A8",
"{u} (Gene) is bound by {v} (Co... | Phenylbutazone (Compound) binds SLC22A8 (Gene) and SLC22A8 (Gene) is bound by Ibuprofen (Compound)
Phenylbutazone may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Ibuprofen
Phenylbutazo... |
DB01068 | DB01377 | 1,565 | 1,283 | [
"DDInter411",
"DDInter1119"
] | Clonazepam | Magnesium oxide | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechan... | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Minor | 0 | [
[
[
1565,
23,
1283
]
],
[
[
1565,
1,
905
],
[
905,
23,
1283
]
],
[
[
1565,
63,
104
],
[
104,
23,
1283
]
],
[
[
1565,
40,
1382
],
[
1382,
... | [
[
[
"Clonazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Clonazepam",
"{u} (Compound) resembles {v} (Compound)",
"Lorazepam"
],
[
"Lorazepam",
"{u} may cause a minor ... | Clonazepam (Compound) resembles Lorazepam (Compound) and Lorazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a minor interaction that can... |
DB11915 | DB12364 | 1,293 | 1,421 | [
"DDInter1909",
"DDInter200"
] | Valbenazine | Betrixaban | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Moderate | 1 | [
[
[
1293,
24,
1421
]
],
[
[
1293,
24,
1017
],
[
1017,
24,
1421
]
],
[
[
1293,
63,
1151
],
[
1151,
24,
1421
]
],
[
[
1293,
64,
760
],
[
760... | [
[
[
"Valbenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Valbenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
... | Valbenazine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Valbenazine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunit... |
DB00446 | DB09118 | 597 | 1,580 | [
"DDInter351",
"DDInter1711"
] | Chloramphenicol | Stiripentol | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
597,
24,
1580
]
],
[
[
597,
23,
466
],
[
466,
62,
1580
]
],
[
[
597,
24,
1409
],
[
1409,
24,
1580
]
],
[
[
597,
24,
283
],
[
283,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Chloramphenicol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
... | Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Stiripentol
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Apixaban a... |
DB09054 | DB15982 | 384 | 1,339 | [
"DDInter905",
"DDInter193"
] | Idelalisib | Berotralstat | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat ... | Moderate | 1 | [
[
[
384,
24,
1339
]
],
[
[
384,
63,
1101
],
[
1101,
23,
1339
]
],
[
[
384,
62,
222
],
[
222,
23,
1339
]
],
[
[
384,
25,
283
],
[
283,
... | [
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Idelalisib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutra... |
DB00382 | DB01211 | 62 | 609 | [
"DDInter1734",
"DDInter393"
] | Tacrine | Clarithromycin | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
62,
24,
609
]
],
[
[
62,
63,
600
],
[
600,
23,
609
]
],
[
[
62,
24,
752
],
[
752,
23,
609
]
],
[
[
62,
24,
770
],
[
770,
24,
... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidi... |
DB00445 | DB09082 | 322 | 659 | [
"DDInter655",
"DDInter1934"
] | Epirubicin | Vilanterol | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
322,
24,
659
]
],
[
[
322,
63,
1570
],
[
1570,
24,
659
]
],
[
[
322,
24,
927
],
[
927,
63,
659
]
],
[
[
322,
25,
1069
],
[
1069,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and E... |
DB00701 | DB11921 | 1,091 | 1,019 | [
"DDInter90",
"DDInter492"
] | Amprenavir | Deflazacort | Amprenavir is a protease inhibitor used to treat HIV infection. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
1091,
25,
1019
]
],
[
[
1091,
24,
959
],
[
959,
24,
1019
]
],
[
[
1091,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
1091,
25,
629
],
[
629,
... | [
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide"... | Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucapari... |
DB01169 | DB08881 | 57 | 868 | [
"DDInter120",
"DDInter1925"
] | Arsenic trioxide | Vemurafenib | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
57,
25,
868
]
],
[
[
57,
6,
8374
],
[
8374,
45,
868
]
],
[
[
57,
6,
2067
],
[
2067,
46,
868
]
],
[
[
57,
63,
479
],
[
479,
23,
... | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Arsenic trioxide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Arsenic trioxide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Arsenic trioxide (Compound) binds IKBKB (Gene) and IKBKB (Gene) is upregulated by Vemurafenib (Compound)
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Don... |
DB00703 | DB09043 | 997 | 135 | [
"DDInter1167",
"DDInter36"
] | Methazolamide | Albiglutide | A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
997,
24,
135
]
],
[
[
997,
63,
1647
],
[
1647,
23,
135
]
],
[
[
997,
63,
870
],
[
870,
24,
135
]
],
[
[
997,
24,
688
],
[
688,
2... | [
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
... | Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and ... |
DB00400 | DB11689 | 353 | 321 | [
"DDInter843",
"DDInter1659"
] | Griseofulvin | Selumetinib | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Moderate | 1 | [
[
[
353,
24,
321
]
],
[
[
353,
24,
392
],
[
392,
24,
321
]
],
[
[
353,
24,
1297
],
[
1297,
63,
321
]
],
[
[
353,
62,
1101
],
[
1101,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
... | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and O... |
DB04865 | DB11714 | 4 | 1,316 | [
"DDInter1335",
"DDInter610"
] | Omacetaxine mepesuccinate | Durvalumab | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote... | Moderate | 1 | [
[
[
4,
24,
1316
]
],
[
[
4,
63,
167
],
[
167,
24,
1316
]
],
[
[
4,
24,
1136
],
[
1136,
24,
1316
]
],
[
[
4,
24,
270
],
[
270,
63,
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Durvalumab"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases... |
DB00005 | DB00570 | 1,057 | 147 | [
"DDInter687",
"DDInter1936"
] | Etanercept | Vinblastine | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Major | 2 | [
[
[
1057,
25,
147
]
],
[
[
1057,
25,
134
],
[
134,
24,
147
]
],
[
[
1057,
25,
970
],
[
970,
23,
147
]
],
[
[
1057,
25,
37
],
[
37,
6... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinblastine"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u... | Etanercept may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Etanercept may lead to a major life threatening interaction when taken with Fluorouracil and Fluorouracil may cause a minor ... |
DB00323 | DB00366 | 1,062 | 1,594 | [
"DDInter1829",
"DDInter600"
] | Tolcapone | Doxylamine | Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Moderate | 1 | [
[
[
1062,
24,
1594
]
],
[
[
1062,
24,
662
],
[
662,
63,
1594
]
],
[
[
1062,
21,
28709
],
[
28709,
60,
1594
]
],
[
[
1062,
1,
1533
],
[
153... | [
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine
Tolcapone (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused... |
DB00372 | DB00765 | 999 | 1,266 | [
"DDInter1793",
"DDInter1205"
] | Thiethylperazine | Metyrosine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) | Moderate | 1 | [
[
[
999,
24,
1266
]
],
[
[
999,
24,
1551
],
[
1551,
1,
1266
]
],
[
[
999,
24,
662
],
[
662,
24,
1266
]
],
[
[
999,
24,
401
],
[
401,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metyrosine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyldopa"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa and Methyldopa (Compound) resembles Metyrosine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate inte... |
DB00241 | DB08901 | 288 | 1,468 | [
"DDInter257",
"DDInter1492"
] | Butalbital | Ponatinib | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
288,
24,
1468
]
],
[
[
288,
24,
478
],
[
478,
24,
1468
]
],
[
[
288,
23,
752
],
[
752,
23,
1468
]
],
[
[
288,
24,
1135
],
[
1135,
... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Butalbital may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine ... |
DB11793 | DB11901 | 738 | 913 | [
"DDInter1297",
"DDInter107"
] | Niraparib | Apalutamide | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
738,
24,
913
]
],
[
[
738,
24,
110
],
[
110,
62,
913
]
],
[
[
738,
63,
279
],
[
279,
24,
913
]
],
[
[
738,
24,
1320
],
[
1320,
6... | [
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
],
... | Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin and Polatuzumab vedotin may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Anisin... |
DB06637 | DB08865 | 1,109 | 1,593 | [
"DDInter468",
"DDInter448"
] | Dalfampridine | Crizotinib | Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
1109,
24,
1593
]
],
[
[
1109,
21,
28792
],
[
28792,
60,
1593
]
],
[
[
1109,
64,
593
],
[
593,
24,
1593
]
],
[
[
1109,
63,
1645
],
[
16... | [
[
[
"Dalfampridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Dalfampridine",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disor... | Dalfampridine (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Crizotinib (Compound)
Dalfampridine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases wh... |
DB00475 | DB01619 | 1,119 | 830 | [
"DDInter355",
"DDInter1441"
] | Chlordiazepoxide | Phenindamine | An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
1119,
24,
830
]
],
[
[
1119,
24,
537
],
[
537,
40,
830
]
],
[
[
1119,
63,
13
],
[
13,
24,
830
]
],
[
[
1119,
24,
104
],
[
104,
1... | [
[
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
... | Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate in... |
DB00312 | DB00317 | 1,023 | 883 | [
"DDInter1423",
"DDInter810"
] | Pentobarbital | Gefitinib | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Moderate | 1 | [
[
[
1023,
24,
883
]
],
[
[
1023,
24,
594
],
[
594,
40,
883
]
],
[
[
1023,
24,
1195
],
[
1195,
1,
883
]
],
[
[
1023,
6,
10215
],
[
10215,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
... | Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib (Compound) resembles Gefitinib (Compound)
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib (Compound) resembles Gefitinib (Compound)
... |
DB00011 | DB12834 | 1,451 | 148 | [
"DDInter944",
"DDInter1649"
] | Interferon alfa-n1 | Secnidazole | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive ... | Moderate | 1 | [
[
[
1451,
24,
148
]
],
[
[
1451,
24,
1593
],
[
1593,
24,
148
]
],
[
[
1451,
63,
491
],
[
491,
24,
148
]
],
[
[
1451,
25,
1477
],
[
1477,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Pegi... |
DB06595 | DB11642 | 1,491 | 938 | [
"DDInter1214",
"DDInter1480"
] | Midostaurin | Pitolisant | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
1491,
24,
938
]
],
[
[
1491,
62,
112
],
[
112,
23,
938
]
],
[
[
1491,
25,
760
],
[
760,
24,
938
]
],
[
[
1491,
24,
28
],
[
28,
2... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Midostaurin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Midostaurin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant
Midostaurin may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may ca... |
DB00317 | DB01072 | 883 | 915 | [
"DDInter810",
"DDInter129"
] | Gefitinib | Atazanavir | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Moderate | 1 | [
[
[
883,
24,
915
]
],
[
[
883,
24,
1327
],
[
1327,
1,
915
]
],
[
[
883,
6,
4973
],
[
4973,
45,
915
]
],
[
[
883,
21,
28642
],
[
28642,
... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
],
[
... | Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) resembles Atazanavir (Compound)
Gefitinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Atazanavir (Compound)
Gefitinib (Compound) causes Shock (Side Effect) and Shock (Side Effect... |
DB00059 | DB01017 | 1,560 | 1,669 | [
"DDInter1404",
"DDInter1224"
] | Pegaspargase | Minocycline | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Moderate | 1 | [
[
[
1560,
24,
1669
]
],
[
[
1560,
24,
1572
],
[
1572,
1,
1669
]
],
[
[
1560,
24,
1545
],
[
1545,
40,
1669
]
],
[
[
1560,
24,
45
],
[
45,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Minocycline (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Oxytetracycline and Oxytetracycline (Compound) resembles... |
DB12455 | DB14491 | 933 | 428 | [
"DDInter1336",
"DDInter725"
] | Omadacycline | Ferrous fumarate | Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in ani... | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
933,
24,
428
]
],
[
[
933,
63,
1193
],
[
1193,
23,
428
]
],
[
[
933,
63,
1384
],
[
1384,
24,
428
]
],
[
[
933,
63,
1193
],
[
1193,
... | [
[
[
"Omadacycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Omadacycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
... | Omadacycline may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Omadacycline may cause a moderate interaction that could exacerbate diseases when taken with Magal... |
DB00063 | DB01175 | 366 | 318 | [
"DDInter659",
"DDInter672"
] | Eptifibatide | Escitalopram | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Moderate | 1 | [
[
[
366,
24,
318
]
],
[
[
366,
24,
1230
],
[
1230,
1,
318
]
],
[
[
366,
64,
834
],
[
834,
24,
318
]
],
[
[
366,
24,
714
],
[
714,
24... | [
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
... | Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Eptifibatide may lead to a major life threatening interaction when taken with Drotrecogin alfa and Drotrecogin alfa may cause a moderate interaction that co... |
DB08903 | DB11057 | 996 | 720 | [
"DDInter170",
"DDInter1223"
] | Bedaquiline | Mineral oil | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
996,
24,
720
]
],
[
[
996,
25,
927
],
[
927,
63,
720
]
],
[
[
996,
64,
1151
],
[
1151,
24,
720
]
],
[
[
996,
63,
688
],
[
688,
2... | [
[
[
"Bedaquiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Bedaquiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encora... | Bedaquiline may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Bedaquiline may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a moderate i... |
DB00950 | DB09293 | 1,413 | 116 | [
"DDInter732",
"DDInter954"
] | Fexofenadine | Iodide I-131 | Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamin... | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Moderate | 1 | [
[
[
1413,
24,
116
]
],
[
[
1413,
1,
1242
],
[
1242,
24,
116
]
],
[
[
1413,
6,
4973
],
[
4973,
45,
1486
],
[
1486,
24,
116
]
],
[
[
1413,
... | [
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Fexofenadine",
"{u} (Compound) resembles {v} (Compound)",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a m... | Fexofenadine (Compound) resembles Cetirizine (Compound) and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Fexofenadine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interactio... |
DB04835 | DB11978 | 1,655 | 124 | [
"DDInter1125",
"DDInter822"
] | Maraviroc | Glasdegib | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1655,
24,
124
]
],
[
[
1655,
63,
79
],
[
79,
24,
124
]
],
[
[
1655,
24,
98
],
[
98,
24,
124
]
],
[
[
1655,
24,
159
],
[
159,
63,... | [
[
[
"Maraviroc",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Maraviroc",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
... | Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may ... |
DB05679 | DB14783 | 1,683 | 287 | [
"DDInter1907",
"DDInter574"
] | Ustekinumab | Diroximel fumarate | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1683,
24,
287
]
],
[
[
1683,
63,
1101
],
[
1101,
24,
287
]
],
[
[
1683,
24,
812
],
[
812,
24,
287
]
],
[
[
1683,
25,
1583
],
[
1583,
... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
]... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab ... |
DB01240 | DB06700 | 885 | 643 | [
"DDInter657",
"DDInter511"
] | Epoprostenol | Desvenlafaxine | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | Moderate | 1 | [
[
[
885,
24,
643
]
],
[
[
885,
63,
1100
],
[
1100,
1,
643
]
],
[
[
885,
21,
28709
],
[
28709,
60,
643
]
],
[
[
885,
25,
292
],
[
292,
... | [
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],... | Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Epoprostenol (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Desvenlafaxine (Compound)
Epoprostenol... |
DB00603 | DB09036 | 303 | 812 | [
"DDInter1137",
"DDInter1668"
] | Medroxyprogesterone acetate | Siltuximab | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Moderate | 1 | [
[
[
303,
24,
812
]
],
[
[
303,
63,
362
],
[
362,
24,
812
]
],
[
[
303,
24,
4
],
[
4,
24,
812
]
],
[
[
303,
23,
700
],
[
700,
24,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when ... |
DB00445 | DB00726 | 322 | 1,164 | [
"DDInter655",
"DDInter1876"
] | Epirubicin | Trimipramine | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Moderate | 1 | [
[
[
322,
24,
1164
]
],
[
[
322,
24,
1237
],
[
1237,
40,
1164
]
],
[
[
322,
63,
508
],
[
508,
40,
1164
]
],
[
[
322,
64,
576
],
[
576,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Trimipramine (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Trimipramine (Comp... |
DB00197 | DB13007 | 1,324 | 1,060 | [
"DDInter1881",
"DDInter642"
] | Troglitazone | Enfortumab vedotin | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
1324,
24,
1060
]
],
[
[
1324,
24,
129
],
[
129,
23,
1060
]
],
[
[
1324,
24,
1593
],
[
1593,
24,
1060
]
],
[
[
1324,
63,
1179
],
[
1179... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Crizoti... |
DB00774 | DB01261 | 1,577 | 170 | [
"DDInter889",
"DDInter1679"
] | Hydroflumethiazide | Sitagliptin | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
1577,
24,
170
]
],
[
[
1577,
21,
28921
],
[
28921,
60,
170
]
],
[
[
1577,
24,
52
],
[
52,
62,
170
]
],
[
[
1577,
24,
708
],
[
708,
... | [
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Hydroflumethiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Sid... | Hydroflumethiazide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Sitagliptin (Compound)
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a minor interaction that can limit clinical effects when t... |
DB01234 | DB08904 | 1,220 | 375 | [
"DDInter513",
"DDInter342"
] | Dexamethasone | Certolizumab pegol | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
1220,
25,
375
]
],
[
[
1220,
62,
1461
],
[
1461,
23,
375
]
],
[
[
1220,
23,
1193
],
[
1193,
62,
375
]
],
[
[
1220,
64,
704
],
[
704,
... | [
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
... | Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate ... |
DB09078 | DB11986 | 1,228 | 484 | [
"DDInter1036",
"DDInter648"
] | Lenvatinib | Entrectinib | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
1228,
24,
484
]
],
[
[
1228,
62,
1247
],
[
1247,
23,
484
]
],
[
[
1228,
63,
1539
],
[
1539,
24,
484
]
],
[
[
1228,
24,
1662
],
[
1662,... | [
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Lenvatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Lenvatinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin an... |
DB00635 | DB04865 | 1,573 | 4 | [
"DDInter1515",
"DDInter1335"
] | Prednisone | Omacetaxine mepesuccinate | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
1573,
24,
4
]
],
[
[
1573,
7,
11955
],
[
11955,
46,
4
]
],
[
[
1573,
6,
1899
],
[
1899,
46,
4
]
],
[
[
1573,
18,
20113
],
[
20113,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Prednisone",
"{u} (Compound) upregulates {v} (Gene)",
"SYNGR3"
],
[
"SYNGR3",
"{u} (Gene) is upre... | Prednisone (Compound) upregulates SYNGR3 (Gene) and SYNGR3 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Prednisone (Compound) binds NR3C1 (Gene) and NR3C1 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Prednisone (Compound) downregulates IER3 (Gene) and IER3 (Gene) is upregulated by Omac... |
DB01044 | DB09564 | 246 | 1,296 | [
"DDInter809",
"DDInter930"
] | Gatifloxacin | Insulin degludec | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Major | 2 | [
[
[
246,
25,
1296
]
],
[
[
246,
25,
1411
],
[
1411,
24,
1296
]
],
[
[
246,
24,
659
],
[
659,
24,
1296
]
],
[
[
246,
64,
1645
],
[
1645,
... | [
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Insulin degludec"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
... | Gatifloxacin may lead to a major life threatening interaction when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilantero... |
DB00863 | DB06817 | 1,194 | 809 | [
"DDInter1568",
"DDInter1563"
] | Ranitidine | Raltegravir | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. | Minor | 0 | [
[
[
1194,
23,
809
]
],
[
[
1194,
21,
28893
],
[
28893,
60,
809
]
],
[
[
1194,
24,
478
],
[
478,
23,
809
]
],
[
[
1194,
40,
1127
],
[
1127,... | [
[
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Raltegravir"
]
],
[
[
"Ranitidine",
"{u} (Compound) causes {v} (Side Effect)",
"Hallucination"
],
[
"Hallucination",
"{u} (Side Effect) ... | Ranitidine (Compound) causes Hallucination (Side Effect) and Hallucination (Side Effect) is caused by Raltegravir (Compound)
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a minor interaction that can limit clinical effects when taken with Ra... |
DB00005 | DB09570 | 1,057 | 1,480 | [
"DDInter687",
"DDInter1002"
] | Etanercept | Ixazomib | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Major | 2 | [
[
[
1057,
25,
1480
]
],
[
[
1057,
24,
987
],
[
987,
63,
1480
]
],
[
[
1057,
24,
268
],
[
268,
24,
1480
]
],
[
[
1057,
25,
453
],
[
453,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazomib"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live anti... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Etanercept may cause a moderate interact... |
DB00046 | DB00703 | 1,179 | 997 | [
"DDInter940",
"DDInter1167"
] | Insulin lispro | Methazolamide | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. | Moderate | 1 | [
[
[
1179,
24,
997
]
],
[
[
1179,
24,
471
],
[
471,
1,
997
]
],
[
[
1179,
24,
1572
],
[
1572,
23,
997
]
],
[
[
1179,
24,
1669
],
[
1669,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Acetazolamide and Acetazolamide (Compound) resembles Methazolamide (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline may cause a minor ... |
DB01234 | DB09037 | 1,220 | 920 | [
"DDInter513",
"DDInter1413"
] | Dexamethasone | Pembrolizumab | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and ... | Moderate | 1 | [
[
[
1220,
24,
920
]
],
[
[
1220,
1,
891
],
[
891,
24,
920
]
],
[
[
1220,
40,
1573
],
[
1573,
24,
920
]
],
[
[
1220,
25,
1019
],
[
1019,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pembrolizumab"
]
],
[
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may ca... | Dexamethasone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Pembrolizumab
Dexamethasone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00204 | DB00468 | 228 | 1,424 | [
"DDInter580",
"DDInter1557"
] | Dofetilide | Quinine | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Major | 2 | [
[
[
228,
25,
1424
]
],
[
[
228,
6,
8374
],
[
8374,
45,
1424
]
],
[
[
228,
18,
3106
],
[
3106,
57,
1424
]
],
[
[
228,
21,
29316
],
[
29316,... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
]
],
[
[
"Dofetilide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Quinine"
... | Dofetilide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Quinine (Compound)
Dofetilide (Compound) downregulates DNAJA3 (Gene) and DNAJA3 (Gene) is downregulated by Quinine (Compound)
Dofetilide (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Quinine (Compound)
Dofetilide ... |
DB00197 | DB01364 | 1,324 | 22 | [
"DDInter1881",
"DDInter650"
] | Troglitazone | Ephedrine | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Moderate | 1 | [
[
[
1324,
24,
22
]
],
[
[
1324,
24,
1529
],
[
1529,
63,
22
]
],
[
[
1324,
24,
1445
],
[
1445,
1,
22
]
],
[
[
1324,
24,
1220
],
[
1220,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedr... |
DB02701 | DB14730 | 1,632 | 1,412 | [
"DDInter1289",
"DDInter264"
] | Nicotinamide | Calaspargase pegol | An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
1632,
24,
1412
]
],
[
[
1632,
24,
5
],
[
5,
24,
1412
]
],
[
[
1632,
63,
1144
],
[
1144,
24,
1412
]
],
[
[
1632,
64,
1377
],
[
1377,
... | [
[
[
"Nicotinamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Nicotinamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
... | Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Nategli... |
DB00060 | DB00685 | 912 | 1,299 | [
"DDInter947",
"DDInter1887"
] | Interferon beta-1a | Trovafloxacin | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Moderate | 1 | [
[
[
912,
24,
1299
]
],
[
[
912,
24,
328
],
[
328,
62,
1299
]
],
[
[
912,
63,
816
],
[
816,
23,
1299
]
],
[
[
912,
24,
552
],
[
552,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trovafloxacin"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercapto... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken w... |
DB01133 | DB11110 | 1,104 | 603 | [
"DDInter1808",
"DDInter1115"
] | Tiludronic acid | Magnesium citrate | Tiludronate, or (4-chlorophenyl)thio-methylene-1,1-bisphosphonate, is a first generation bisphosphonate similar to [etidronic acid] and [clodronic acid].[A1923,A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. Tiludronic acid was first described ... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
1104,
24,
603
]
],
[
[
1104,
24,
1151
],
[
1151,
24,
603
]
],
[
[
1104,
63,
544
],
[
544,
24,
603
]
],
[
[
1104,
24,
1151
],
[
1151,
... | [
[
[
"Tiludronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Tiludronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"... | Tiludronic acid may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Tiludronic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnes... |
DB05676 | DB12095 | 1,513 | 179 | [
"DDInter111",
"DDInter1760"
] | Apremilast | Telotristat ethyl | Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
1513,
24,
179
]
],
[
[
1513,
24,
214
],
[
214,
24,
179
]
],
[
[
1513,
63,
1324
],
[
1324,
24,
179
]
],
[
[
1513,
24,
971
],
[
971,
... | [
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],... | Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Troglitazo... |
DB00041 | DB00099 | 1,648 | 440 | [
"DDInter38",
"DDInter735"
] | Aldesleukin | Filgrastim | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Moderate | 1 | [
[
[
1648,
24,
440
]
],
[
[
1648,
24,
37
],
[
37,
63,
440
]
],
[
[
1648,
64,
1451
],
[
1451,
24,
440
]
],
[
[
1648,
25,
147
],
[
147,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Aldesleukin may lead to a major life threatening interaction when taken with Interferon alfa-n1 and Interferon al... |
DB00014 | DB00308 | 521 | 347 | [
"DDInter839",
"DDInter901"
] | Goserelin | Ibutilide | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Major | 2 | [
[
[
521,
25,
347
]
],
[
[
521,
25,
540
],
[
540,
1,
347
]
],
[
[
521,
21,
29118
],
[
29118,
60,
347
]
],
[
[
521,
23,
112
],
[
112,
... | [
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibutilide"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} (C... | Goserelin may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone (Compound) resembles Ibutilide (Compound)
Goserelin (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Ibutilide (Compound)
Goserelin may cause a minor interaction that can limit cl... |
DB00478 | DB01156 | 1,369 | 593 | [
"DDInter1597",
"DDInter252"
] | Rimantadine | Bupropion | An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza. | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
1369,
25,
593
]
],
[
[
1369,
21,
28757
],
[
28757,
60,
593
]
],
[
[
1369,
23,
752
],
[
752,
23,
593
]
],
[
[
1369,
24,
1383
],
[
1383,... | [
[
[
"Rimantadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Rimantadine",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Com... | Rimantadine (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Bupropion (Compound)
Rimantadine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Bupropion
... |
DB00333 | DB12141 | 576 | 971 | [
"DDInter1166",
"DDInter817"
] | Methadone | Gilteritinib | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Major | 2 | [
[
[
576,
25,
971
]
],
[
[
576,
23,
112
],
[
112,
23,
971
]
],
[
[
576,
25,
485
],
[
485,
24,
971
]
],
[
[
576,
25,
823
],
[
823,
63,... | [
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Methadone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Methadone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Methadone may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may ca... |
DB11113 | DB11978 | 657 | 124 | [
"DDInter307",
"DDInter822"
] | Castor oil | Glasdegib | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of, which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic,... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
657,
24,
124
]
],
[
[
657,
63,
1079
],
[
1079,
24,
124
]
],
[
[
657,
24,
180
],
[
180,
63,
124
]
],
[
[
657,
24,
1612
],
[
1612,
... | [
[
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
... | Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine and Olicer... |
DB01058 | DB11979 | 978 | 1,320 | [
"DDInter1510",
"DDInter625"
] | Praziquantel | Elagolix | Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infecti... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
978,
24,
1320
]
],
[
[
978,
63,
1249
],
[
1249,
24,
1320
]
],
[
[
978,
25,
129
],
[
129,
24,
1320
]
],
[
[
978,
24,
1155
],
[
1155,
... | [
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
],
[
... | Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Praziquantel may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may ca... |
DB00009 | DB01242 | 1,271 | 1,237 | [
"DDInter56",
"DDInter410"
] | Alteplase | Clomipramine | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
1271,
24,
1237
]
],
[
[
1271,
64,
1578
],
[
1578,
24,
1237
]
],
[
[
1271,
24,
1274
],
[
1274,
24,
1237
]
],
[
[
1271,
25,
498
],
[
498... | [
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",... | Alteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may caus... |
DB00186 | DB11186 | 905 | 1,609 | [
"DDInter1092",
"DDInter1427"
] | Lorazepam | Pentoxyverine | Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm. | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
905,
24,
1609
]
],
[
[
905,
24,
104
],
[
104,
24,
1609
]
],
[
[
905,
40,
523
],
[
523,
24,
1609
]
],
[
[
905,
25,
475
],
[
475,
... | [
[
[
"Lorazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Lorazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[... | Lorazepam may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Lorazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that ... |
DB00398 | DB09020 | 79 | 28 | [
"DDInter1702",
"DDInter212"
] | Sorafenib | Bisacodyl | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
79,
24,
28
]
],
[
[
79,
7,
2797
],
[
2797,
46,
28
]
],
[
[
79,
18,
20113
],
[
20113,
46,
28
]
],
[
[
79,
6,
7428
],
[
7428,
46,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Sorafenib",
"{u} (Compound) upregulates {v} (Gene)",
"ATF3"
],
[
"ATF3",
"{u} (Gene) is upregulated by {v} (Compou... | Sorafenib (Compound) upregulates ATF3 (Gene) and ATF3 (Gene) is upregulated by Bisacodyl (Compound)
Sorafenib (Compound) downregulates IER3 (Gene) and IER3 (Gene) is upregulated by Bisacodyl (Compound)
Sorafenib (Compound) binds HIPK3 (Gene) and HIPK3 (Gene) is upregulated by Bisacodyl (Compound)
Sorafenib (Compound) u... |
DB00842 | DB01233 | 686 | 1,311 | [
"DDInter1359",
"DDInter1197"
] | Oxazepam | Metoclopramide | Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feat... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
686,
24,
1311
]
],
[
[
686,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
686,
24,
649
],
[
649,
63,
1311
]
],
[
[
686,
63,
662
],
[
662,
... | [
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Oxazepam",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is ca... | Oxazepam (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Metoc... |
DB04948 | DB09082 | 1,084 | 659 | [
"DDInter1083",
"DDInter1934"
] | Lofexidine | Vilanterol | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
1084,
24,
659
]
],
[
[
1084,
24,
927
],
[
927,
63,
659
]
],
[
[
1084,
25,
1069
],
[
1069,
24,
659
]
],
[
[
1084,
24,
1450
],
[
1450,
... | [
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Lofexidine may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may caus... |
DB09135 | DB13985 | 1,211 | 546 | [
"DDInter967",
"DDInter1108"
] | Ioxilan | Lutetium Lu 177 dotatate | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dot... | Major | 2 | [
[
[
1211,
25,
546
]
],
[
[
1211,
64,
50
],
[
50,
24,
546
]
],
[
[
1211,
64,
629
],
[
629,
25,
546
]
],
[
[
1211,
64,
50
],
[
50,
24,... | [
[
[
"Ioxilan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Ioxilan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfasalazine"
],
[
"Sulfasalazine"... | Ioxilan may lead to a major life threatening interaction when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Ioxilan may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to a... |
DB00465 | DB00620 | 886 | 175 | [
"DDInter1010",
"DDInter1855"
] | Ketorolac | Triamcinolone | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Moderate | 1 | [
[
[
886,
24,
175
]
],
[
[
886,
24,
1573
],
[
1573,
1,
175
]
],
[
[
886,
24,
617
],
[
617,
40,
175
]
],
[
[
886,
63,
251
],
[
251,
1,... | [
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
... | Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Triamcinolone (Compound)
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Triamcinolone (Compou... |
DB00501 | DB06603 | 752 | 39 | [
"DDInter380",
"DDInter1387"
] | Cimetidine | Panobinostat | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Moderate | 1 | [
[
[
752,
24,
39
]
],
[
[
752,
23,
112
],
[
112,
23,
39
]
],
[
[
752,
24,
479
],
[
479,
23,
39
]
],
[
[
752,
24,
336
],
[
336,
24,
... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Cimetidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Don... |
DB00307 | DB11601 | 1,101 | 1,270 | [
"DDInter202",
"DDInter1889"
] | Bexarotene | Tuberculin purified protein derivative | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
1101,
24,
1270
]
],
[
[
1101,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
1101,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
1101,
63,
599
],
[
599... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Bexarotene may lead to a major life threatening interaction when taken with Cladri... |
DB00188 | DB00284 | 168 | 1,647 | [
"DDInter222",
"DDInter11"
] | Bortezomib | Acarbose | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Moderate | 1 | [
[
[
168,
24,
1647
]
],
[
[
168,
7,
10643
],
[
10643,
46,
1647
]
],
[
[
168,
18,
4893
],
[
4893,
57,
1647
]
],
[
[
168,
7,
9384
],
[
9384,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
]
],
[
[
"Bortezomib",
"{u} (Compound) upregulates {v} (Gene)",
"EAPP"
],
[
"EAPP",
"{u} (Gene) is upregulated by {v} (Compo... | Bortezomib (Compound) upregulates EAPP (Gene) and EAPP (Gene) is upregulated by Acarbose (Compound)
Bortezomib (Compound) downregulates S100A13 (Gene) and S100A13 (Gene) is downregulated by Acarbose (Compound)
Bortezomib (Compound) upregulates TRIB3 (Gene) and TRIB3 (Gene) is downregulated by Acarbose (Compound)
Bortez... |
DB00262 | DB01042 | 552 | 1,307 | [
"DDInter302",
"DDInter1144"
] | Carmustine | Melphalan | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Moderate | 1 | [
[
[
552,
24,
1307
]
],
[
[
552,
5,
11555
],
[
11555,
44,
1307
]
],
[
[
552,
54,
19138
],
[
19138,
15,
1307
]
],
[
[
552,
21,
28766
],
[
28... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Carmustine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease... | Carmustine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Melphalan (Compound)
Carmustine (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Melphalan (Compound)
Carmustine (Compound) causes Hypotensio... |
DB05812 | DB11703 | 1,374 | 405 | [
"DDInter8",
"DDInter9"
] | Abiraterone | Acalabrutinib | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
1374,
24,
405
]
],
[
[
1374,
64,
690
],
[
690,
24,
405
]
],
[
[
1374,
25,
982
],
[
982,
63,
405
]
],
[
[
1374,
63,
758
],
[
758,
... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifabutin"
],
[
"Rifabu... | Abiraterone may lead to a major life threatening interaction when taken with Rifabutin and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Abiraterone may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate i... |
DB06366 | DB09054 | 1,007 | 384 | [
"DDInter1434",
"DDInter905"
] | Pertuzumab | Idelalisib | Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA ... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1007,
24,
384
]
]
] | [
[
[
"Pertuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
]
] | |
DB00193 | DB00986 | 534 | 1,192 | [
"DDInter1841",
"DDInter834"
] | Tramadol | Glycopyrronium | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Moderate | 1 | [
[
[
534,
24,
1192
]
],
[
[
534,
24,
1511
],
[
1511,
63,
1192
]
],
[
[
534,
24,
262
],
[
262,
24,
1192
]
],
[
[
534,
6,
2720
],
[
2720,
... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
... | Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidi... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.